Navigation Links
Osprey Pharmaceuticals U.S.A., Inc. Completes $11 Million Initial Private Financing
Date:9/3/2008

SAN FRANCISCO, Sept. 3 /PRNewswire/ -- Osprey Pharmaceuticals U.S.A., a privately-held company focused on developing novel protein therapeutics that selectively target chemokine-activated leukocytes that are responsible for initiating and maintaining inflammatory diseases, announced today that the company has raised $11 million in its first round of venture capital funding. The financing was led by Burrill & Company with participation from Novo Nordisk Biotech Fund (Novo Nordisk's internal corporate venture fund), Yasuda Enterprise Development, GeneChem Therapeutics Venture Fund, BDC Venture Capital, Inc. and Western Technology Seed Investment Fund.

"With a lead compound poised to enter clinical studies and a rich pipeline of highly specific protein therapeutics designed to target chemokine-mediated inflammation, we are enthusiastic about the opportunity to invest in Osprey Pharmaceuticals U.S.A.," said John E. Hamer, Ph.D., Managing Partner of Burrill & Company on behalf of the company's investors. "The company has acquired a powerful drug discovery platform which has the potential to yield new high value therapeutics against inflammatory and autoimmune disease."

Osprey Pharmaceuticals U.S.A. will deploy these funds to advance the company's lead product, a therapeutic fusion protein known as CCL2-LPM, into a safety and proof-of-concept clinical trial. CCL2-LPM is designed to target the CCL2-CCR2 chemokine ligand and receptor axis, which play a significant role in inflammatory kidney diseases and other autoimmune and inflammatory conditions. Proceeds will also be applied to the discovery and development of additional therapeutics that have emerged from the company's proprietary platform for the discovery of therapeutic Leukocyte Population Modulators (LPMs). LPMs specifically target chemokine-activated leukocytes that drive and/or maintain a variety of inflammatory and autoimmune disorders.

"We are pleased to have received strong support
'/>"/>

SOURCE Osprey Pharmaceuticals U.S.A., Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Osprey Pharmaceuticals Names Jack M. Anthony as CEO
2. Jack Anthony to Resign From VaxGens Board After Accepting CEO Position at Osprey Pharmaceuticals
3. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
4. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
7. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
8. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
9. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
10. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
11. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... BOSTON , Oct. 22, 2014  Actavis plc ... pharmaceutical company, and Rhythm, a biopharmaceutical company, today announced ... acquire Rhythm,s wholly owned subsidiary, Rhythm Health, Inc., which ... the treatment of diabetic gastroparesis and other GI functional ... Phase 2 trial of relamorelin for the treatment of ...
(Date:10/22/2014)... NJ (PRWEB) October 22, 2014 ... and services – has been working with a team ... and New Haven Farms Community Farming Collaborative to provide ... ePRO solution. The study, which started in May, ... program that provides participants weekly exposure to and participation ...
(Date:10/22/2014)... Md. , Oct. 22, 2014   Synthetic ... developing novel pathogen-specific therapies for serious infections and diseases, ... has issued a Notice of Allowance for a composition ... its C. difficile program, SYN-004. This is ... SYN-004 in the U.S. and adds to the Company,s ...
(Date:10/20/2014)... 2014 The report “Pharmacy Automation ... Packaging and Labeling Systems, Table-top Counters) by End-user ... Forecasts & Trends to 2019” analyzes and studies ... North America, Europe, Asia-Pacific, and the Rest of ... and 30 figures spread through 300 pages and ...
Breaking Biology Technology:Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 2Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 3Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 4Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 5myPROpad™ Topic of Panel Discussion at the Yale Food Systems Symposium 2myPROpad™ Topic of Panel Discussion at the Yale Food Systems Symposium 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 2Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 3Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 4
... - Wisconsin is slowly getting over its shyness ... Wisconsin and Midwestern small business executives is learning more ... Small Business Innovation Research-Small Business Technology Transfer Conference at ... ,The two congressionally mandated programs, one (SBIR) designed to ...
... dayparting tactics and strategies that can improve the ... Google AdWords tactics were limited to four big ... Google began offering ad scheduling in 2006, it ... spending and optimize the effectiveness of campaigns using ...
... venture investors have fewer secrets these days, and they ... early-stage executives during the National SBIR-STTR Conference. , ,In ... the University of Wisconsin-Madison , they counseled technology ... sustainable market advantage, and what each round of funding ...
Cached Biology Technology:Wisconsin firms urged to pursue federal SBIR dollars 2Wisconsin firms urged to pursue federal SBIR dollars 3Getting the most from Google dayparts 2Getting the most from Google dayparts 3Early-stage executives hear from investors 2Early-stage executives hear from investors 3
(Date:10/15/2014)... awarded the 44th Rosenstiel Award for Distinguished Work in ... exploring the mechanisms of genomic instability and its implications ... the second alumnus to win the Rosenstiel Award; the ... , Alt is the Charles A. Janeway Professor of ... and an investigator at the Howard Hughes Medical Institute ...
(Date:10/14/2014)... (Oct. 14, 2014)—It,s been millions of years since ... team led by Ohio University scientists is breathing life ... airflow through dinosaur snouts. The research has important implications ... breathe but to enhance the sense of smell and ... animals," said Ohio University doctoral student Jason Bourke, lead ...
(Date:10/14/2014)... Montreal, October 14, 2014 – High doses of fish oil ... fibrillation, a common type of irregular heartbeat in which the ... The results of the AFFORD trial led by the Montreal ... American College of Cardiology on October 7th. , For ... antiarrhythmic therapy were randomly assigned to 4 grams of fish ...
Breaking Biology News(10 mins):Brandeis awards 44th Rosenstiel Award to pioneering geneticist Fred Alt 2Dinosaur breathing study shows that noses enhanced smelling and cooled brain 2Dinosaur breathing study shows that noses enhanced smelling and cooled brain 3
... feathers to stand out and attract mates, according to a ... Doňana in Seville, Spain, and colleagues. Their research is the ... from the secretions of their uropygial gland for cosmetic reasons. ... of birds and is situated near the base of the ...
... Applications International Corporation (SAIC) (NYSE: SAI ) announced ... the U. S. Department of Defense (DoD), Biometrics Identity Management ... to the U.S. Central Command,s (USCENTCOM) area of responsibility (AOR). ... performance, two one year options and a total value of ...
... effects, such as dead bottoms and massive blooms of ... effects on acidification. Researchers at the University of Gothenburg, ... out the aggregate effects of various environmental measures. ... by many different processes at the same time and ...
Cached Biology News:Beauty from the bottom up 2SAIC Awarded $23 Million Task Order by Defense Biometrics Identity Management Agency 2Mathematical model may result in better environment measures for the Baltic 2
... a fluorescence scanner with 1 or 2 ... Protein, CGH, ) spotted on standard slides ... InnoScan700 scanners include three different models:, ... simultaneous dual fluorescence scanner (635nm and 532nm). ...
... Non-Radioactive Translation Detection Systems allow non-radioactive ... Using these systems, biotinylated lysine residues ... translation, eliminating the need for labeling ... acids. This biotinylated lysine is added ...
... Maximize the value of your microarray ... offer the support you need from ... the most up to date methods. ... the Gene Expression Profiling Service or ...
... your microarray data using Asuragens bioinformatics ... need from consultation to extensive data ... date methods. Utilize our expertise in ... Service or from your own microarray ...
Biology Products: